First-Line Treatment Approved for Stage IV Colorectal Cancer

There is new first-line treatment (standard of care to start treatment) giving as many as 60% of the stage IV colorectal cancer patients more options for treatment. Previously, most stage IV patients undergoing chemotherapy would be recommended to go on FOLFOX and bevacizumab (Avastin). Patients would receive this first set of drugs (called first-line) and if…  Read More

GRATITUDE FOR YOUR GENEROSITY: Our First Two-Year Research Grant

by Mary Miller Fight Colorectal Cancer is thrilled to announce during this holiday season that thanks to the generous donations made to the Lisa Fund, it will be awarding its first-ever two-year $100,000 grant to a scientist whose work fights advanced stage colorectal cancer. Andrea Bertotti, MD, PhD, of the Institute for Cancer Research and Treatment…  Read More

Erbitux Approved as First-Line Treatment

The FDA has approved Erbitux™ (cetuximab) in combination with FOLFIRI for first-line treatment of patients with metastatic colorectal cancer whose tumors have a wild-type (WT) KRAS gene.  Erbitux was first approved in 2004 for patients whose cancer was not responding to available treatments. FDA’s action was prompted by results from a look back at patient outcomes and…  Read More

COIN: No Benefit Found Adding Cetuximab to FOLFOX or CAPOX in First-Line CRC Treatment

Even in colorectal cancer patients with wild-type KRAS mutations, there was no increase in overall survival time or in the time it took before cancer progressed when Erbitux® (cetuximab) was added to FOLFOX or CAPOX chemotherapy. More tumors got smaller with Erbitux treatment, but there was an increase in both serious gastrointestinal toxicity and severe skin…  Read More

Personalizing Personalized Medicine

On Monday, April 25th, Fight Colorectal Cancer held a free patient webinar that tackled the somewhat complex but fascinating topic of personalized medicine. Personalized medicine is what the cancer community calls treatments that are tailored to each patient’s genetic makeup. It is the future of cancer care and in some cases, it is already making a…  Read More

Mutations are Not All the Same

We are making significant progress in understanding what genetic alterations in tumors really mean. Over the last two years, we have learned or the first time that there is an alteration in a gene called KRAS in colon cancer, and tumors which have this mutation do not respond to treatment with Erbitux® (cetuximab) or Vectibix® (panitumumab).…  Read More